Dr. Andrea Apolo

I'm actually excited about the TAR system. The TAR 200 is with gemcitabine, but I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other drugs.

I'm actually excited about the TAR system. The TAR 200 is with gemcitabine, but I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other drugs.

I'm actually excited about the TAR system. The TAR 200 is with gemcitabine, but I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other drugs.

active therapies in there so i'm really excited about it and i think we do need something that kind of manages the bladder right so we have these great systemic therapies but although most patients when they're responding to systemic therapies also respond within the bladder it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches and this may be a way of doing it intensifying

active therapies in there so i'm really excited about it and i think we do need something that kind of manages the bladder right so we have these great systemic therapies but although most patients when they're responding to systemic therapies also respond within the bladder it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches and this may be a way of doing it intensifying

active therapies in there so i'm really excited about it and i think we do need something that kind of manages the bladder right so we have these great systemic therapies but although most patients when they're responding to systemic therapies also respond within the bladder it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches and this may be a way of doing it intensifying

treatment with these tar systems and then leaving the bladder intact.

treatment with these tar systems and then leaving the bladder intact.

treatment with these tar systems and then leaving the bladder intact.

Yeah, this is this to me, it's like a dream come true. So we've always given patients platinum based chemotherapy for bladder cancer with really not that impressive results. But, you know, we've done a lot of trials and we really struggle to do better than platinum based chemotherapy. And now we're doing this in the metastatic setting and we're bringing it to the perioperative setting.

Yeah, this is this to me, it's like a dream come true. So we've always given patients platinum based chemotherapy for bladder cancer with really not that impressive results. But, you know, we've done a lot of trials and we really struggle to do better than platinum based chemotherapy. And now we're doing this in the metastatic setting and we're bringing it to the perioperative setting.

Yeah, this is this to me, it's like a dream come true. So we've always given patients platinum based chemotherapy for bladder cancer with really not that impressive results. But, you know, we've done a lot of trials and we really struggle to do better than platinum based chemotherapy. And now we're doing this in the metastatic setting and we're bringing it to the perioperative setting.

So I think it's a really exciting time where we can actually play around with the therapies that we have in terms of designing clinical trials and find the best treatment options for patients and hopefully in the future, spare their bladder and improve their overall survival, which is really the goal.

So I think it's a really exciting time where we can actually play around with the therapies that we have in terms of designing clinical trials and find the best treatment options for patients and hopefully in the future, spare their bladder and improve their overall survival, which is really the goal.

So I think it's a really exciting time where we can actually play around with the therapies that we have in terms of designing clinical trials and find the best treatment options for patients and hopefully in the future, spare their bladder and improve their overall survival, which is really the goal.

Yeah, so I was so excited to see the results of this study, especially after last year, we saw the really exciting results of EV plus PEMBRO in the metastatic setting. And then we saw the Checkmate 901 data, where when nivolumab was added to GEMSYS, it did better than just GEMSYS alone. And that just kind of set the stage for the perioperative trials that are

Yeah, so I was so excited to see the results of this study, especially after last year, we saw the really exciting results of EV plus PEMBRO in the metastatic setting. And then we saw the Checkmate 901 data, where when nivolumab was added to GEMSYS, it did better than just GEMSYS alone. And that just kind of set the stage for the perioperative trials that are

Yeah, so I was so excited to see the results of this study, especially after last year, we saw the really exciting results of EV plus PEMBRO in the metastatic setting. And then we saw the Checkmate 901 data, where when nivolumab was added to GEMSYS, it did better than just GEMSYS alone. And that just kind of set the stage for the perioperative trials that are

ongoing right now, and Niagara was the first one to report its outcome. And, you know, once I saw that the Checkmate 901 study was positive, that adding nivolumab actually did improve outcomes to platinum-based chemotherapy, but to cisplatinum-based chemotherapy, it didn't have as strong effect with carboplatinum. So that was...

ongoing right now, and Niagara was the first one to report its outcome. And, you know, once I saw that the Checkmate 901 study was positive, that adding nivolumab actually did improve outcomes to platinum-based chemotherapy, but to cisplatinum-based chemotherapy, it didn't have as strong effect with carboplatinum. So that was...